http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
Mohammad Shojaie,Armin Abtahian,Armin Abtahian,Mohamed Amin Ghobadifar,Azadeh Esmail Pour,Armin Akbarzadeh 대한가정의학회 2015 Korean Journal of Family Medicine Vol.36 No.1
Ba ckground: This study aimed to evaluate some of the major risk factors of myocardial infarction including dehydroepiandrosterone sulfate in patients with premature myocardial infarction (age <50 years old) and myocardial infarction (age ≥50 years). Me thods: This is a parallel case-control study on 50 premature myocardial infarction patients and 50 myocardial infarction patients. We also recruited 50 matched participants for each of the two groups. Patients and their control groups were assessed for dehydroepiandrosterone sulfate serum level, diabetes mellitus, hyperlipidemia, hypertriglyceridemia, and hypertension. In addition, family history of cardiovascular disease and current smoking was recorded. Univariate and multivariate logistic regression analyses were performed to evaluate predictors of premature myocardial infarction and myocardial infarction. Re sults: No significant differences were observed between the demographic data of patients and their controls. The dehydroepiandrosterone sulfate serum level was significantly higher in patients with premature myocardial infarction compared with controls. Multivariate logistic regression analysis revealed only serum dehydroepiandrosterone sulfate dehydroepiandrosterone sulfate level to be significantly associated with premature myocardial infarction (odds ratio, 2.65; 95% confidence interval, 1.44 to 4.877; P = 0.002). Additionally, hypertension was found to be associated with myocardial infarction. Co nclusion: Higher levels of serum dehydroepiandrosterone sulfate level are associated with premature myocardial infarction but not with myocardial infarction, and this association is independent of the effects of other risk factors.
Nader Dehghani,Mohamad Reza Fouladivanda,Mohamed Amin Ghobadifar,Gelayol Safshekan-Esfahani,Armin Akbarzadeh 전남대학교 의과학연구소 2015 전남의대학술지 Vol.51 No.1
The current study aimed to determine the efficacy of probing with adjunctive mitomycinC (MMC) as a treatment for nasolacrimal duct obstruction (NLDO) in adults and tostudy the association of probing success with demographic and obstructioncharacteristics. This was a prospective, randomized, double-blind, placebo-controlledtrial including 140 patients (each with a unilateral NLDO) scheduled for nasolacrimalprobing who were randomly assigned to receive MMC (0.2 mg/ml, 70 patients; groupA) or placebo (normal saline, 70 patients; group B). Irrigation was carried out with 0.5cc of MMC (0.2 mg/mL) in the duct with a nasal pack for 10 minutes in group A. Patients’postprobing epiphora was evaluated at 2 weeks and 1, 3, 6, and 9 monthspostoperatively. Probing was judged to be a success if there was no or mild wateringfor at least 9 months after the procedure. There were no significant differences betweenthe two study groups in demographic characteristics or duration of the operation(p=0.062). The overall success rate of probing with MMC was 47/70 (67.1%), which wassignificantly higher than the success rate of the procedure with placebo (p=0.0027). When the sex of the patients was controlled for by logistic regression, a significant associationbetween the failure rate of probing and increasing age was found in cases andcontrols (p=0.004 vs. p=0.006, respectively). No significant side effects of probing withMMC were noted after 9 months of follow-up. Administering MMC in a dosage of 0.2mg/mL during nasolacrimal probing significantly increased the success rate of probing. The failure rate of probing increased with age. A low dose of MMC is cheap, safe, andeasily accessible; thus, it is recommended during nasolacrimal probing, especially inpatients who refuse dacryocystorhinostomy surgery.